通过促进铁化,ANK1可以抑制骨髓瘤的恶性进展
Fei Zhang1, Junming Wan2, Jinghua Zhong3
1Department of Orthopaedics, First Affiliated Hospital of Gannan Medical University, No. 23, Qingnian Road, Zhanggong District, Ganzhou City, 341000, Jiangxi Province, China.
BMC cancer
|August 31, 2024
概括
安基林1 (ANK1) 通过促进细胞死亡途径铁灭亡来抑制骨髓瘤的进展. 这项研究确定ANK1是改善骨髓瘤预后的关键生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 骨髓瘤 (OS) 是一种高度恶性的原发性骨瘤,预后不佳.
- 铁亡是一种受调节的细胞死亡形式,越来越多地被认为在OS的发展和进展中发挥着关键作用.
研究的目的:
- 评估Ankyrin 1 (ANK1) 对骨髓瘤的作用.
- 研究ANK1影响OS进展的特定分子机制,特别是其在铁亡中的作用.
主要方法:
- 微阵列数据集的生物信息学分析,以确定OS中的关键基因.
- 使用转染的OS细胞 (U-2OS,MG-63) 进行体外研究,以评估ANK1对细胞活力,迁移和入侵的影响.
- 在OS小鼠模型中的体内实验,包括组织学和亡分析 (H&E,IHC,TUNEL染色).
主要成果:
- 确定ANK1作为与OS预后和免疫透相关的关键枢纽基因.
- 证明ANK1过度表达抑制OS细胞的增殖,迁移和入侵,同时促进铁亡.
- 在体内证实,ANK1过度表达抑制瘤生长,增强亡,并减少增殖标志物.
结论:
- 安基林1 (ANK1) 作为骨质肉瘤的预后生物标志物.
- 通过诱导铁亡,ANK1可以减轻OS的进展,提供潜在的治疗点.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


